The hidden cost of pulmonary arterial hypertension (PAH): quantifying work productivity loss in working-age adults, Journal of Medical Economy, March 5, 2026

Using US health insurance data from 2019 to 2023, a study recently published in the Journal of Medical Economy quantified the number of workdays lost annually by working-age adults with pulmonary arterial hypertension due to medical appointments and care. The cost of this lost productivity was estimated using average household income as a benchmark. The […]

The hidden cost of pulmonary arterial hypertension (PAH): quantifying work productivity loss in working-age adults, Journal of Medical Economy, March 5, 2026 Read Post »

“Health at a Glance: Europe 2024” report by the Organisation for Economic Co-operation and Development (OECD) analyzes critical challenges confronting European health systems

The Organisation for Economic Co-operation and Development (OECD) “Health at a Glance: Europe 2024” report analyzes critical challenges confronting European health systems following the COVID-19 pandemic. Two thematic chapters anchor the publication. The opening chapter delivers an in-depth analysis of Europe’s health workforce crisis. It examines the root causes of personnel shortages and outlines policy

“Health at a Glance: Europe 2024” report by the Organisation for Economic Co-operation and Development (OECD) analyzes critical challenges confronting European health systems Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States, Pharmacoeconomics, October 12, 2024

A study published on Pharmacoeconomics on October 12 reveals that pulmonary arterial hypertension continues to be associated with a very high economic burden and healthcare resource utilization across all payer types within the US healthcare system. The study included 11,670 patients enrolled in Medicare Fee-for-Service, 1,021 patients enrolled in Medicare Advantage, 274 patients enrolled in

Economic Burden Associated with Pulmonary Arterial Hypertension in the United States, Pharmacoeconomics, October 12, 2024 Read Post »

PHA UK’s “sister” website, phocusonlifestyle.org, is addressed at patients and caregivers and houses a wealth of support resources and pulmonary hypertension patient stories

http://www.phocusonlifestyle.org is the “sister” website to that of the UK Pulmonary Hypertension, PHA UK. It is aimed at patients and peers supporting each other through stories. It also houses written resources covering a very wide range of issues related to living with pulmonary hypertension including:

PHA UK’s “sister” website, phocusonlifestyle.org, is addressed at patients and caregivers and houses a wealth of support resources and pulmonary hypertension patient stories Read Post »

TRANSLATE »
Scroll to Top